Long Acting rFactor lX: Phase I/IIa started

Biovitrum and Biogen’s Syntonix Pharmaceuticals Inc. unit began an open-label, single-ascending dose, U.S. Phase I/IIa trial to evaluate six dose levels of intravenous FIX:Fc in patients. ...